Subscribe
africa-studio-shutterstock-com-5
Africa Studio / Shutterstock.com
9 June 2016Americas

Judge overturns $200m award in Gilead v Merck

A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US Supreme Court refuses to hear appeal against ‘unclean hands’ decision
10 January 2019   The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
US Supreme Court refuses to hear appeal against ‘unclean hands’ decision
10 January 2019   The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

More on this story

Americas
US Supreme Court refuses to hear appeal against ‘unclean hands’ decision
10 January 2019   The US Supreme Court has refused to hear an appeal against a ruling that American pharmaceutical firm Merck & Co cannot collect $200 million in damages due to its misconduct during a trial.
Americas
Federal Circuit affirms Merck ‘unclean hands’ verdict
26 April 2018   The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.
Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB